Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA 2984653 C · Owner: Ganymed Pharmaceuticals Gmbh · Inventors: Sahin, Ugur; Helftenbein, Gerd; Schluter, Volker
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
According to the invention, tumour-associated gene products and nucleic acids coding therefor were identified. The present invention relates to the therapy and diagnosis of diseases wherein said tumour-associated gene products are expressed aberrantly. The invention also relates to proteins polypeptides and peptides which are expressed in a tumour-associated manner and the nucleic acids coding therefor.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 23, 2004 and granted December 15, 2020. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 23, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 23, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.